Scil Proteins

About us
Affilin®-based protein therapeutics and non-therapeutic applications using its proprietary flexible and modular Affilin® platform for partners in the pharmaceutical, biotech and life science industries. Scil proteins is a private protein engineering company focused on generating and optimizing unique.

Affilin®-based molecules are derived from human scaffold proteins and have high stability, affinity and specificity making them ideal for a range of applications that demand and capture biomolecules. The unique properties of these Affilin®-based molecules have overcome several of the limitations of antibodies, especially in specific nucleic applications.

The company’s core business areas include the development of drug conjugates and multi-specific protein binding molecules, as well as ligands for non-therapeutic applications. All of these core areas are underpinned by state-of-the-art protein engineering technologies and a team with an unrivaled depth of expertise and track record in this area, making Scil Proteins an attractive partner.

Scil Proteins was founded in 1999 at the Technology and Founder Center in Halle / Saale, Germany. The company is fully owned by BioNet Ventures GmbH. In 2014 BioNet Ventures sold Scil Proteins’ sister company and microbial manufacturing specialist Scil Proteins Production to Wacker Biotech GmbH. Bionet Ventures remains the sole shareholder of Scil Proteins.